← Back to headlines
Cogent Bioscience Files New Drug Application for Bezuclastinib
Cogent Bioscience (COGT) has submitted a New Drug Application (NDA) for its drug candidate Bezuclastinib, marking a key step towards potential regulatory approval.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
Bill Gates Warns of AI Risks and Urges Immediate Government Regulation
13m ago
U.S. July Inflation Data Sparks Market Losses and Raises Rate Hike Concerns
14m ago
U.S. Core Inflation Holds Steady at 3.3% in July as Energy Costs Persist
17m ago
Recent Corporate Earnings Releases Highlight Divergent Financial Performance
30m ago